GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinocelltech Group Ltd (SHSE:688520) » Definitions » Financial Strength

Sinocelltech Group (SHSE:688520) Financial Strength : 4 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Sinocelltech Group Financial Strength?

Sinocelltech Group has the Financial Strength Rank of 4.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Sinocelltech Group's Interest Coverage for the quarter that ended in Mar. 2025 was 2.78. Sinocelltech Group's debt to revenue ratio for the quarter that ended in Mar. 2025 was 1.32. As of today, Sinocelltech Group's Altman Z-Score is 5.28.


Competitive Comparison of Sinocelltech Group's Financial Strength

For the Biotechnology subindustry, Sinocelltech Group's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinocelltech Group's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinocelltech Group's Financial Strength distribution charts can be found below:

* The bar in red indicates where Sinocelltech Group's Financial Strength falls into.


;
;

Sinocelltech Group Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Sinocelltech Group's Interest Expense for the months ended in Mar. 2025 was ¥-21 Mil. Its Operating Income for the months ended in Mar. 2025 was ¥59 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥972 Mil.

Sinocelltech Group's Interest Coverage for the quarter that ended in Mar. 2025 is

Interest Coverage=-1*Operating Income (Q: Mar. 2025 )/Interest Expense (Q: Mar. 2025 )
=-1*59.06/-21.232
=2.78

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Sinocelltech Group's Debt to Revenue Ratio for the quarter that ended in Mar. 2025 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2025 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1763.857 + 971.904) / 2078.948
=1.32

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Sinocelltech Group has a Z-score of 5.28, indicating it is in Safe Zones. This implies the Z-Score is strong.

Good Sign:

Altman Z-score of 5.28 is strong.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinocelltech Group  (SHSE:688520) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Sinocelltech Group has the Financial Strength Rank of 4.


Sinocelltech Group Financial Strength Related Terms

Thank you for viewing the detailed overview of Sinocelltech Group's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinocelltech Group Business Description

Traded in Other Exchanges
N/A
Address
Kechuang Seventh Street, Beijing Economic and Technological Development Zone, Room 307, Building 5, Courtyard 31, Beijing, CHN, 100176
Sinocelltech Group Ltd is engaged in development and industrialization of biopharmaceutical products such as monoclonal antibodies, recombinant proteins and vaccines. The company has developed technology platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. Its capacities include stable CHO cell line development, cell banking and certification, serum-free and protein-free culture medium development, fed-batch cell culture process development, optimization, and process scale-up; protein purification development, and large scale production.
Executives
Xie Liang Zhi Director

Sinocelltech Group Headlines

No Headlines